Clinical Trial Update: Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating an autologous dendritic cell vaccine for recurrent respiratory papillomatosis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Papillomatosis

Drugs mentioned

• Autologous dendritic cell vaccine (dendritic cell vaccine)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Respiratory Papillomatosis | Phase 1 | Status: RECRUITING